Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

October
22
2018

Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018

BOCA RATON, Fla., Oct. 22, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management…

October
19
2018

Dermatology Times – As an add-on to Mohs surgery, this treatment may have its benefits

Superficial Radio Therapy and our CEO, Joe Sardano, are making headlines with Dermatology Times. This article highlights the benefits of using SRT alongside Mohs surgery when treating skin cancer patients. With 80 percent of skin…

October
18
2018

Physician Spotlight – January 2019

Dr. Steven K. Grekin, D.O. is the founder and Medical Director of The Grekin Skin Institute, a dermatological practice providing care within many segments of the medical market in Michigan. His primary mission is to…

October
17
2018

Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel’s Largest Hospital for Skin Cancer and Keloid Treatment

SRT-100 Vision Coming to Patients at Sheba Medical Center Near Tel Aviv BOCA RATON, Fla., Oct. 17, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy